ASCO 2021 June 4 - 8th, 2021

Join Us (Virtually) at 2021 ASCO

George Clinical’s deep oncology research expertise will be on display this month during the 2021 ASCO Annual Meeting. Several leaders will be featured in sessions during the conference including Lee Schwartzberg, Ari VanderWalde, Herbert Loong, Ralph Boccia, Timothy Pluard and Jason Chandler.


Follow these links to view their abstracts:

Ari VanderWalde

Herbert Loong

Ralph Boccia

Timothy Pluard


For more information on our scientific leaders, their abstracts and how we can support your study, please contact Matthew Reabold at [email protected]

George Clinical's Leadership in Attendance

Dr. Schwartzberg’s research interests include breast cancer, supportive care and developmental therapeutics. He is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno; and a founding Chief Medical Officer at OneOncology.. He was recently involved with genomic profiling of advanced cancer and is interested in visionary approaches to clinical research and oncology science. He divides his time between patients in the clinic and conducting clinical research trials and programmatic development.

A renowned expert in the study and treatment of breast cancer, precision medicine and supportive care, Dr. Schwartzberg is a member of the Board of Directors for the National Comprehensive Cancer Network and is the founding editor-in-chief of the journal Community Oncology. He is also the current editor-in-chief of the Practice Update Oncology website and serves on the editorial board for both the Journal of Supportive Oncology and the ASCO Post.

Dr. Boccia’s research interest is in cancers of the blood and blood-forming tissues as well as solid tumors, such as those seen in bladder cancer. He is Medical Director of the Center for Cancer and Blood Disorders in Bethesda, Maryland, and Clinical Associate Professor of Medicine at Georgetown University in Washington, DC. He also serves as the Chief Medical Officer for the International Oncology Network (ION). He conducts research in exploring the latest advances in colorectal cancer treatment and offers individualized care to patients with focus on multi-modal treatment regimens.

Dr. Boccia has studied and published cancer patients’ supportive care data on cytokine support for chemotherapy-induced anemia and leukopenia, and cytoprotective agents; specifically, amifostine (Ethyol) administration schedules designed to reduce side effects and improve safety. He is a member of numerous professional societies including the American College of Physicians, American Society of Clinical Oncology, American Society of Hematology, and the American Society for Blood and Marrow Transplantation.

Dr. VanderWalde’s primary research is in melanoma, immunotherapy and targeted therapies based on immune markers and aberrations in cancer genetics. He is Vice President of Clinical Development, Caris Life Sciences, and Senior Medical Director, George Clinical. A thought leader in melanoma and clinical trial design and implementation, he has collaborated on advisory boards with many of the nation’s thought leaders and top experts in the field and previously served as United States Medical Lead and Clinical Research Medical Director with Amgen Inc., directing U.S. global development of talimogene laherparepvec, a novel viral-based immunotherapeutic that has shown efficacy in late-stage clinical trials in melanoma.

As Former Director of Research at West Cancer Center and Research Institute, Dr. VanderWalde was responsible for managing the portfolio of all clinical trials. He is the former Director of Precision Oncology at OneOncology.

Dr. Loong’s clinical interests include sarcoma medical oncology, neuro-oncology, thoracic oncology and experimental therapeutics (Phase I clinical trials). He is based in Hong Kong and holds conjoint appointments of Clinical Assistant Professor in the Department of Clinical Oncology and Deputy Medical Director of the Phase I Clinical Trials Centre of The Chinese University of Hong Kong. He is also the current and founding convenor of the Prince of Wales Hospital Adult Sarcoma Multidisciplinary Team. He has conducted over 50 oncology Phase I, II and III trials as either a Principal Investigator or Co-Investigator and is interested in actively helping to develop further capacity for oncology research within the APAC region.

Dr. Loong obtained his medical degree from The University of Hong Kong and completed a Fellowship in Drug Development at Princess Margaret Cancer Centre in Toronto, Canada with a special focus on Experimental Therapeutics. He is a recipient of the European Cancer Congress Fellowship Grant (2013), the ASCO Annual Meeting Merit Award (2014), the Hong Kong College of Physicians Young Investigators’ Award (2014). Nominated by patients and their caregivers, Dr. Loong led the Lung Cancer Team at CUHK to be bestowed the IASLC Foundation Cancer Care Team Award in recognition for providing the best thoracic oncology care in “Asia & Rest of the World” in 2018.


Dr. Pluard’s research is focused on new targeted therapies of breast cancer. He is Medical Director, Saint Luke’s Cancer Institute and Koontz Center for Advanced Breast Cancer, Kansas City, MO. Previously, he was Associate Professor of Medicine and Clinical Director of Breast Oncology at Washington University Siteman Cancer Center in St. Louis. He specializes in offering comprehensive care including advanced genomic and immunotherapy treatments to women with metastatic breast cancer and advises patients on participating in clinical trials for leading-edge treatments.

Dr. Pluard leads a team at St. Luke’s Cancer Institute focused on the comprehensive care of women with breast cancer where every woman’s tumor is genetically analyzed to understand what is driving their cancer. He emphasizes the importance of in-depth communication with patients taking a fully holistic approach to their treatment options. With his work at Saint Luke’s, Koontz Center and in clinical trials, Dr. Pluard strives to help define care for all women with advanced breast cancer.

Dr. Chandler specializes in medical oncology, hematology and blood cancers. He is Director of Research for Hematology Malignancies at West Cancer Center. Dr. Chandler was a co-leader in the efforts to gain FDA approval for the delivery of CAR-T therapy to cancer patients in 2019, paving the way for CAR-T therapies and treatments to be tested across the country. He is interested in research and immunology and committed to providing patients with access to early-stage clinical trials.

Event Location

Attending this event?

Meet with George Clinical! Contact us to schedule a time now.

    I agree to the handling of my personal information in accordance with the George Clinical privacy policy.

    Please input this code: captcha

    Add George Clinical to your network